All Stories

  1. Investigational HIV integrase inhibitors in phase I and phase II clinical trials

    Article • Expert Opinion on Investigational Drugs, September 2017, Taylor & Francis

    Thibault MESPLEDE, Dr Mark Wainberg

  2. The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration

    Article • mBio, April 2017, ASM Journals

    Dr Mark Wainberg

  3. JAK-STAT Signaling Pathways and Inhibitors Affect Reversion of Envelope-Mutated HIV-1

    Article • Journal of Virology, February 2017, ASM Journals

    Dr Mark Wainberg

  4. Might dolutegravir be part of a functional cure for HIV?1

    Article • Canadian Journal of Microbiology, May 2016, Canadian Science Publishing

    Dr Mark Wainberg, Thibault MESPLEDE

  5. Identification of a Pyridoxine-Derived Small-Molecule Inhibitor Targeting Dengue Virus RNA-Dependent RNA Polymerase

    Article • Antimicrobial Agents and Chemotherapy, November 2015, ASM Journals

    Dr Mark Wainberg

  6. Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239

    Article • Journal of Virology, September 2015, ASM Journals

    Dr Mark Wainberg, Thibault MESPLEDE

  7. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance

    Article • Journal of Virology, August 2015, ASM Journals

    Dr Mark Wainberg, Thibault MESPLEDE

  8. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity

    Article • Journal of Virology, August 2015, ASM Journals

    Dr Mark Wainberg, Thibault MESPLEDE

  9. Subtype-Specific Analysis of the K65R Substitution in HIV-1 That Confers Hypersusceptibility to a Novel Nucleotide-Competing Reverse Transcriptase Inhibitor

    Article • Antimicrobial Agents and Chemotherapy, March 2015, ASM Journals

    Dr Mark Wainberg

  10. Combination of the R263K and M184I/V Resistance Substitutions against Dolutegravir and Lamivudine Decreases HIV Replicative Capacity

    Article • Antimicrobial Agents and Chemotherapy, February 2015, ASM Journals

    Dr Mark Wainberg, Thibault MESPLEDE

  11. Dolutegravir Resistance Mutation R263K Cannot Coexist in Combination with Many Classical Integrase Inhibitor Resistance Substitutions

    Article • Journal of Virology, February 2015, ASM Journals

    Dr Mark Wainberg, Thibault MESPLEDE

  12. Simian-Tropic HIV as a Model To Study Drug Resistance against Integrase Inhibitors

    Article • Antimicrobial Agents and Chemotherapy, January 2015, ASM Journals

    Dr Mark Wainberg, Thibault MESPLEDE

  13. Differential Effects of the G118R, H51Y, and E138K Resistance Substitutions in Different Subtypes of HIV Integrase

    Article • Journal of Virology, December 2014, ASM Journals

    Dr Mark Wainberg, Thibault MESPLEDE

  14. The R262K Substitution Combined with H51Y in HIV-1 Subtype B Integrase Confers Low-Level Resistance against Dolutegravir

    Article • Antimicrobial Agents and Chemotherapy, October 2014, ASM Journals

    Dr Mark Wainberg, Thibault MESPLEDE

  15. HIV-1 Group O Integrase Displays Lower Enzymatic Efficiency and Higher Susceptibility to Raltegravir than HIV-1 Group M Subtype B Integrase

    Article • Antimicrobial Agents and Chemotherapy, September 2014, ASM Journals

    Dr Mark Wainberg, Thibault MESPLEDE

  16. Effect of HIV-1 Integrase Resistance Mutations When Introduced into SIVmac239 on Susceptibility to Integrase Strand Transfer Inhibitors

    Article • Journal of Virology, June 2014, ASM Journals

    Dr Mark Wainberg, Thibault MESPLEDE

  17. Effects of the W153L Substitution in HIV Reverse Transcriptase on Viral Replication and Drug Resistance to Multiple Categories of Reverse Transcriptase Inhibitors

    Article • Antimicrobial Agents and Chemotherapy, May 2014, ASM Journals

    Dr Mark Wainberg

  18. The Connection Domain Mutation N348I in HIV-1 Reverse Transcriptase Enhances Resistance to Etravirine and Rilpivirine but Restricts the Emergence of the E138K Resistance Mutation by Diminishing Viral Replication Capacity

    Article • Journal of Virology, November 2013, ASM Journals

    Dr Mark Wainberg

  19. Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 Integrase

    Article • Antimicrobial Agents and Chemotherapy, September 2013, ASM Journals

    Dr Mark Wainberg, Thibault MESPLEDE

  20. Role of the K101E Substitution in HIV-1 Reverse Transcriptase in Resistance to Rilpivirine and Other Nonnucleoside Reverse Transcriptase Inhibitors

    Article • Antimicrobial Agents and Chemotherapy, September 2013, ASM Journals

    Dr Mark Wainberg

  21. Basis for Early and Preferential Selection of the E138K Mutation in HIV-1 Reverse Transcriptase

    Article • Antimicrobial Agents and Chemotherapy, July 2013, ASM Journals

    Dr Mark Wainberg

  22. Latent HIV-1 Can Be Reactivated by Cellular Superinfection in a Tat-Dependent Manner, Which Can Lead to the Emergence of Multidrug-Resistant Recombinant Viruses

    Article • Journal of Virology, June 2013, ASM Journals

    Dr Mark Wainberg

  23. Productive Entry of HIV-1 during Cell-to-Cell Transmission via Dynamin-Dependent Endocytosis

    Article • Journal of Virology, May 2013, ASM Journals

    Dr Mark Wainberg, Thibault MESPLEDE

  24. Effect of Mutations at Position E138 in HIV-1 Reverse Transcriptase and Their Interactions with the M184I Mutation on Defining Patterns of Resistance to Nonnucleoside Reverse Transcriptase Inhibitors Rilpivirine and Etravirine

    Article • Antimicrobial Agents and Chemotherapy, April 2013, ASM Journals

    Dr Mark Wainberg